Back to Journals » OncoTargets and Therapy » Volume 9 » Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials
Please verify you are not a robot.